Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINIMISE-STEMI: MRA Pretreatment in STEMI
NCT01882179Phase 3Completed
- Sponsor
- University College London
- Start
- Nov 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of potassium canrenoate, spironolactone in ST elevation myocardial infarction (STEMI), sponsored by University College London. Started Nov 2013; status: completed.
02
Drugs
potassium canrenoatespironolactone
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT01882179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882179.